Cancer Genetics and Epigenetics, 2025, Vol.13, No.1, 32-40 http://medscipublisher.com/index.php/cge 32 Feature Review Open Access Study on the Impact of Patient Genotyping on Targeted Therapy for Cervical Cancer Hui Xu Tianjin Medical University Cancer Institute and Hospital, Hexi, 300210, Tianjin, China Corresponding email: xuhui@163.com Cancer Genetics and Epigenetics, 2025, Vol.13, No.1 doi: 10.5376/cge.2025.13.0004 Received: 20 Dec., 2024 Accepted: 27 Jan., 2024 Published: 14 Feb., 2025 Copyright © 2025 Xu, This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Preferred citation for this article: Xu H., 2025, Study on the impact of patient genotyping on targeted therapy for cervical cancer, Cancer Genetics and Epigenetics, 13(1): 32-40 (doi: 10.5376/cge.2025.13.0004) Abstract The patient's genotyping affects the targeted treatment of cervical cancer, and the study particularly emphasizes its role in precision medicine. Through genomic analysis, scientists have discovered some key genes, such as PIK3CA, PTEN, and ERBB3. Some mutations in these genes can be used for treatment and can help improve the treatment effect. Studies have found that tumor mutation burden (TMB) and some specific genetic changes can be used to predict the patient's survival time and help doctors decide which treatment plan to use. If genotyping is added to daily treatment, more personalized treatment methods can be developed that are more suitable for each person. The study also mentioned several new technologies, such as next-generation sequencing (NGS), multi-omics analysis, and CRISPR diagnostic technology, and also pointed out some challenges, such as the high cost of these technologies, which may not be available to some patients, and the problem of inconsistent data standards. Genotyping is a promising method that can make treatment more targeted and bring more new options to patients, greatly improving treatment effects and patient prognosis, and may completely change the treatment of cervical cancer. Keywords Cervical cancer; Patient genotyping; Targeted therapy; Precision medicine; Genomic analysis; Tumor mutation burden; Next-generation sequencing; Personalized therapy; CRISPR diagnostics; Multi-omics approach 1 Introduction Cervical cancer is still a major health problem worldwide and is the fourth most common cancer in women (Barra et al., 2017; Almeida et al., 2019). In 2020 alone, there were approximately 604 127 new cases worldwide, which shows that it is still a serious problem (Crowley et al., 2021). Although there have been some advances in HPV vaccines and screening technologies, cervical cancer is still one of the leading causes of death in some places where these resources are not available (Áyen et al., 2020; Ferrall et al., 2021). Many patients are already in the late stage when they are discovered, and there are not many treatments at this time, and the effect is not good, so we are in great need of more effective treatments (Bao et al., 2021). Now, the development of precision medicine has brought new possibilities for the treatment of cervical cancer, especially in genotyping and targeted therapy. We can analyze the genes of tumors, find key mutations in them, and then design specialized treatment plans. Many cervical cancer patients can find some treatable genetic changes, such as mutations in oncogenes such as PIK3CA and ERBB2 (Services et al., 2017; Friedman et al., 2023). Using this genetic information for actual treatment can customize personalized plans for each patient and help improve the treatment effect (Crowley et al., 2021). This study aims to analyze the genetic characteristics of cervical cancer patients and find out the key mutations that may affect the treatment effect. The goal of the study is to make the treatment of cervical cancer more precise and help improve the survival rate and quality of life of patients. By gaining a deeper understanding of the genetic mechanism of this disease, we hope to be able to tailor personalized treatment methods for each patient in the future, making the treatment more accurate and effective. 2 Pathogenesis and Genetic Factors of Cervical Cancer 2.1 Molecular mechanism of cervical cancer development Cervical cancer is mainly caused by long-term infection with high-risk human papillomavirus (HPV), which is a
RkJQdWJsaXNoZXIy MjQ4ODYzNA==